Created by:
Elizabeth Wilkinson, San Jose, CA
Secretary, California Hepatitis C Task Force For the National Association of
Hepatitis Task Forces
and
Dick Southern
California State Council, Vietnam Veterans of America
This is the most comprehensive single compilation of disclosed clinical
trials found at one internet link for both government and privately funded
projects for Hepatitis A, B, C and hepatitis vaccines available at this
time. This database is categorized by state, with investigators contact info
and brief indication of research topic. It is not a 100% complete list, so
your help is always welcomed should you have new or additional information
to add. Contact Liz at: elwilkinson@sbcglobal.net.
Search results for ( "OTHER" OR "FED" OR "INDUSTRY" OR "NIH" ) [FUNDED-BY]
AND hepatitis c [CONDITION] AND "United States" [LOCATION-COUNTRY] AND
"California" [LOCATION-STATE] are shown below:
Include trials that are no longer recruiting patients.
1. Recruiting Pegasys in Combination with Copegus in Previously
Untreated Patients with Chronic Hepatitis C virus Genotype 2 or 3
Condition: Chronic Hepatitis C
2. Recruiting Pegasys in Combination with Copegus in Previously
Untreated Patients with Chronic Hepatitis C Genotype 1
Condition: Chronic Hepatitis C
3. Recruiting Evaluation of the viral kinetics and pharmacokinetics
of Pegasys plus Copegus and PEG-Intron plus Rebetol in patients with Chronic
Hepatitis C and previously untreated with an interferon.
Condition: Hepatitis C
4. Recruiting A Caspase Inhibitor in Chronic Hepatitis C (HCV)
Patients
Condition: Hepatitis C, Chronic
5. Recruiting PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis
C Subjects Who Failed Response to alpha-Interferon Plus Ribavirin
Conditions: Chronic Hepatitis C; Liver Fibrosis; Cirrhosis
6. Recruiting Effects of Ribavirin on Zidovudine or Stavudine
Conditions: HIV Infections; Hepatitis C
7. Recruiting Efficacy and safety of Pegasys plus Copegus in patients
with chronic Hepatitis C who are unable to tolerate or who do not respond to
12 weeks of therapy with PEG-Intron plus Rebetol/Ribavirin.
Condition: Hepatitis C
8. Recruiting Pegylated Interferon Alfa-2a Maintenance Therapy and
Liver Disease Progression in People Infected With Both HIV and Hepatitis C
Virus (HCV)
Conditions: HIV Infections; Hepatitis C; Liver Disease
9. Recruiting Peg-Ifn Dose Evaluations for Previously Untreated
Subjects with Chronic Hepatitis C Infected w/ Genotype 1
Condition: Chronic Hepatitis C
10. Recruiting Prevention of Disease Progress in Chronic HepC Pts
Significant Liver Fibrosis who failed PEG-Intron + Rebetol in P02370
Conditions: Chronic Hepatitis C; Liver Fibrosis
11. Recruiting Peg-Intron for Prevention of Disease Progression in
Chronic Hepatitis C Patients with Cirrhosis who failed with a Interferon
plus Ribavirin Therapy
Conditions: Chronic Hepatitis C; Cirrhosis
12. Recruiting Addition of ISIS 14803 to Therapy with Peginterferon
and Ribavirin for Chronic Hepatitis C (HCV) patients not Responding
Adequately to the Two Drugs
Condition: Hepatitis C, Chronic
13. Recruiting Safety, feasibility and tolerability of Pegasys plus
Copegus in previous intravenous drug users (IVDUs) who are infected with
Chronic Hepatitis C and are currently enrolled in a methadone maintenance
treatment program
Condition: Hepatitis C
14. Recruiting Daily dosing of Interferon Alfacon-1 plus Ribavirin
for treatment of Hepatitis C Infected Patients (nonresponders)
Condition: Chronic Hepatitis C
15. Recruiting CIFN and IFN c-1b with or without Ribavirin for
treatment of Chronic Hepatitis C (nonresponders)
Condition: Chronic Hepatitis C
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act
